Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

Special Report

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

A recent study reported that silmitasertib, an investigational drug currently in development for cancer, may help reduce motor deficits and neuropathology in a Huntington disease.

Therapeutic Potential of Silmitasertib Observed in Huntington Disease Mouse Model

Although valiltramiprosate failed to distinguish itself from placebo on the primary end point, the drug performed significantly better among mild MCI participants vs those with mild Alzheimer disease.

Valiltramiprosate Demonstrates Greater Promise in Milder Forms of Alzheimer Disease, Phase 3 APOLLOE4 Study Shows

Research suggests that CSF ATI ratios could serve as a biomarker for identifying patients with Alzheimer disease at higher risk of ARIA during lecanemab treatment, aiding in safer patient management.

Higher CSF Aß42/Total Tau Ratio Associated With Increased ARIA Risk in Lecanemab

Eli Lilly’s expanded LillyDirect platform tackles barriers in Alzheimer disease diagnosis and care, offering telehealth and in-person options through Healthgrades and Synapticure, with a focus on timely access and patient support.

Eli Lilly Announces Expanded Services to Early Diagnosis and Access Alzheimer Disease Care

Senior vice president of research at The ALS Association. 

Videos

The senior vice president of research at The ALS Association talked about a multidisciplinary session presented at the 2025 MDA Conference that highlighted diverse strategies for neural repair, from pharmacological targets to noninvasive brain stimulation. [WATCH TIME: 6 minutes]

Exploring Multimodal Approaches to Neural Regeneration: Kuldip Dave, PhD

Marco Meglio, Assistant Managing Editor for 

, has been with the team since October 2019. Follow him on Twitter 

In this final episode, neurologists discuss the role of advanced imaging, like OCT, in diagnosing and managing MS, emphasizing the need for further research to optimize its clinical application. [WATCH TIME: 2 minutes]

Bridging Neurology and Ophthalmology in Multiple Sclerosis Research

A pair of neurologists provide clinical insight on the difficulties with identifying and differentiating optic neuritis in various autoimmune conditions like multiple sclerosis and neuromyelitis optica spectrum disorder. [WATCH TIME: 4 minutes]

Challenges in Diagnosing Optic Neuritis in MS and MOGAD

In this third episode, experts delve into the evolving role of optic neuritis and the central vein sign in refining multiple sclerosis diagnosis, highlighting their significance in distinguishing MS from other conditions and ensuring accurate patient care. [WATCH TIME: 3 minutes]

Educating the Clinical Community on Changes to MS Diagnostic Criteria

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

ACTRIMS 2025

MDA 2025

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

News Network

1.125rem

Clinical

 Parkinson disease Disease Spotlight page gives readers key updates and detailed coverage on the most recent expert conversations and data presentations relevant to the treatment of the movement disorder.

Stuart Isaacson, MD, Rajesh Pahwa, MD, and Jennifer Goldman, MD discuss optimizing PD treatment with levodopa and adjunct therapies, addressing patient and pharmacologic challenges, coordinating care, and anticipating the impact of emerging therapies and upcoming Medicare Part D changes.

Medcast Podcasts

Optimizing Parkinson's disease (PD) treatment involves leveraging levodopa and adjunct therapies to address both patient-specific and pharmacologic challenges. Effective management requires coordinated care among healthcare providers to ensure comprehensive treatment strategies. Anticipating the impact of emerging therapies and upcoming changes in Medicare Part D is crucial for adapting treatment plans. These changes may influence drug accessibility and affordability, necessitating proactive adjustments in therapeutic approaches. Understanding these dynamics is essential for improving patient outcomes and maintaining the efficacy of PD management strategies.

Stuart Isaacson, MD, Rajesh Pahwa, MD, and Jennifer Goldman, MD discuss optimizing PD treatment with levodopa and adjunct therapies, addressing patient and pharmacologic challenges, coordinating care, and anticipating the impact of emerging therapies and upcoming Medicare Part D changes.

Multisymptomatic Care in Parkinson's Disease

 is now live! Scroll down to listen, and make sure to subscribe on your favorite streaming service.

 features Dr. Anne Marie Morse, DO, a neurologist with special qualifications in child neurology and a sleep medicine specialist, best known for putting the DAMM in 

 and for always looking for digestible, actionable patient-directed sleep tips, tricks and tools to achieve optimal outcomes. Dr. Morse has joined forces with Brandon Hedgecock, DDS, D-ABDSM, a dentist and founder of Hedgecock Dental and 

; and Matthew Allard, AKA the "Sleep Connector," an experienced sleep professional with 20 years of experience helping others sleep and breathe better nightly, to break down the barriers between dentistry and medicine to develop educational content that considers the whole person and illustrate how sleep relates to lifestyle, wellness, and culture.

Sleeping Around the Podcast realized they had more to give and are a partner with 

Sleeping Around the Podcast × NeurologyLive

 for neurology-focused sleep content to allow any neurology stakeholder to add to their knowledge bank and skillset on how to use sleep as the diagnostic, prognostic, and therapeutic neurology tool it is designed to be.

 – Connection between PD and sleep disorders

 – Overview of study assessing biomarker for EDS in Parkinson disease

 – Role of neurofilament light chain in PD

– Patient demographics and differences of NfL increases 

. Check out the links below to subscribe on your preferred podcast platform.

DAMM Good Sleep

Sleeping Around the Podcast × NeurologyLive brings you a clinical overview of a newly published study highlighting extracellular vesicle-associated miRNA features that could be diagnostically informative of RBD in patients with Parkinson disease.

Sleeping Around the Podcast × NeurologyLive: Candidate Biomarkers to Detect REM Sleep Behavior Disorder in Parkinson Disease

Watch the video version of this episode here. 

Dyskinesia: Importance of Giving Patients More Good “On- Time" in Parkinson’s Disease

Drs Isaacson, Pahwa, and Gupta discuss the management of dyskinesia and providing good ON time in Parkinson’s disease, sharing practical tips for early identification and treatment of dyskinesia, as well as their experience with current treatments.

 – Sleep disturbances as major feature of PD

 – Parkinson-related pathological changes

Sleeping Around the Podcast × NeurologyLive brings you a scientific overview of the crossover between Parkinson disease and sleep disorders. 

Sleeping Around the Podcast × NeurologyLive: Parkinson Disease Awareness Month

To watch the full video episode, follow this link. 

Widening the Therapeutic Window in the Management of Parkinson’s Disease

Expert neurologists discuss strategies to widen the therapeutic window of Parkinson’s disease and options available to treat dyskinesia, providing better control of Parkinson’s disease.

 to subscribe on your favorite streaming service.

The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.

Episode 93, "Caring for Women With Parkinson Disease," features an exclusive interview with 

, an assistant professor of neurology and director of the Parkinson’s Disease & Movement Disorder Program at Global Neurosciences Institute, who spoke with us about the current landscape of care for women with Parkinson disease (PD), how the approach to their care can differ from men, the major gaps around education and treatment for these women, and much more.

, a streaming channel from MJH Life Sciences

. Check out new content and shows every day, only at

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

FDA Issues Complete Response Letter to Amneal for Parkinson Agent IPX203

FDA Grants Traditional Approval to Lecanemab as Therapy for Early-Stage Alzheimer Disease

Medicare Expands Coverage for Fully Approved Alzheimer Agent Lecanemab

FDA Approves Image Guided Programming Software for Vercise Deep Brain Stimulation Systems

 – The presentation of Parkinson disease for women

 – Nonmotor symptoms that can create challenges  for diagnosis

 – OFF episodes and dyskinesia in women vs men

 – Being attentive to patient needs in treatment

 – The daily impact of Parkinson disease

 – Encouraging women with Parkinson to participate in trials

– Conversations in areas of limited knowledge

 to subscribe to the Mind Moments podcast. Be sure to leave a rating and review for the show. Thanks for listening!

Hoping to listen on your favorite podcast app? See below:

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jill Farmer, DO, MPH. [LISTEN TIME: 28 minutes]

Episode 93: Caring for Women With Parkinson Disease

 podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.

Episode 81, "Widening the Therapeutic Window in Parkinson Disease," features an exclusive interview with Robert A. Hauser, MD, MBA, director of the Parkinson’s and Movement Disorders Center at the University of South Florida. He spoke about the current state of therapeutics in Parkinson disease, some of the lingering challenges in day-to-day management, the promise of novel agents in development such as IPX203, and more.

This episode is brought to you by the Giants of Multiple Sclerosis®. This premier neuroscience award program celebrates pioneers, innovators, and future generations of leaders for their remarkable achievements in Multiple Sclerosis. 

Neurelis Files IND for Potentially First Therapy to Treat Cerebral Cavernous Malformations

CDC and FDA Announce Stroke Safety Concern Related to Pfizer-BioNTech Bivalent COVID-19 Vaccine

FDA Hands Eli Lilly Complete Response Letter for Donanemab After Lack of Long-Term Data

FDA Clears Trial Hold on Late-Onset Pompe Disease Gene Therapy AT845

Proclaim XR Spinal Cord Stimulation Wins Approval for Painful Diabetic Peripheral Neuropathy

 – Lingering unmet needs in Parkinson disease management

 – The advances in identifying therapeutic targets in PD

 – Bridging the gap to more effective long-term treatment

 – Overview of IPX203 and its potential to treat PD

 – Safety profile of IPX203 in clinical development

 – The importance of addressing dose-wearing off

 podcast. Be sure to leave a rating and review for the show. Thanks for listening!

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Robert A. Hauser, MD, MBA. [LISTEN TIME: 20 minutes]

Episode 81: Widening the Therapeutic Window in Parkinson Disease

Episode 78, "A Virtual Reality Platform for Parkison Disease," features an exclusive interview with Jay Alberts, PhD, the Edward F. and Barbara A. Bell Endowed Chair at Cleveland Clinic. He joined the show to discuss the complexities that come with understanding early signs of PD, and how the newly designed Cleveland Clinic Virtual Reality Shopping (CC-VRS) platform works towards that, among other topics.

. Check out new episodes of a variety of shows, airing every single day, only on

International Committee Proposes MS Disease Progression Framework Driven by Pathophysiological Mechanisms, Not Clinical Phenotype

Anti-Amyloid-ß Oligomer Antibody ACU193 Gains FDA Fast Track Designation

Duchenne Gene Therapy SRP-9001 Wins Priority Review

Lecanemab Represents Promising Therapy for Alzheimer Disease, Posts Positive Phase 3 Secondary Analyses

Donanemab Shows Greater Ability to Clear Amyloid Plaque Than Aducanumab

Episode Breakdown

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jay Alberts, PhD. [LISTEN TIME: 27 minutes]

Episode 78: A Virtual Reality Platform for Parkinson Disease

The professor of neurology at Northwestern University Feinberg School of Medicine discussed the NSD-ISS and its potential to refine PD diagnosis and clinical trial selection through biomarker-driven staging.

NeuroVoices: Tanya Simuni, MD, FAAN, on Using the Neuronal α-Synuclein Disease Integrated Staging System Framework to Advance Parkinson Disease Staging

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on Parkinson disease.

NeurologyLive® Brain Games: March 9, 2025

The approval was based on data from the ADAPT-PD trial, a prospective study that laid the foundation for aDBS use in a real-world clinical environment.

FDA Approves Medtronic’s Adaptive Deep Brain Stimulation for Parkinson Disease

More than 90% of participants had Parkinson's disease mild cognitive impairment (PD-MCI), highlighting TAK-071’s potential for treating early-stage cognitive decline in Parkinson disease.

M1 Modulatory TAK-091 Improves Cognition in Parkinson Disease, Study Shows

The movement disorder nurse practitioner at Stony Brook Medicine talked about the growing role of artificial intelligence in neurology and emerging treatments for Parkinson disease.

NeuroVoices: Sheryll Baltazar, NP-C, on AI Integration and Emerging Therapies in Neurology 

Looking Ahead: Future Landscape for Treating OFF Time and Dyskinesia

An expert discusses D1 receptor agonists that reduce negative symptoms and the increasing availability of recent and upcoming PUMP options for Parkinson disease treatment.

Balancing Approved Therapies and Patient Preference in Parkinson Disease

An expert discusses the importance of collaborating with patients, emphasizing the value of leading with data when educating them on the efficacy of treatments, and highlights the role of providers in supporting patients as they discover the medications and supplements that work best for them, while advocating for and protecting patients to ensure they can seek the best quality of life.

Providing a Holistic Approach to Parkinson Disease Care

An expert discusses the various forms of therapy offering nutritional support, including exercise and supplements, emphasizing that supplemental therapy, along with medication, is most effective, and highlights the potential benefits of the Mediterranean diet for Parkinson disease.

Selecting the Best Treatment Options for Patients With Parkinson Disease

An expert discusses how patients with dyskinesia are well suited to use pumps and how subcutaneous dopamine agonists avoid the issues previously associated with oral dopamine agonists.

Exciting Pipeline Therapeutics for Parkinson Disease

An expert discusses upcoming advancements in Parkinson disease treatments, including the potential release of the ND0612 pump later this year, demonstrating efficacy comparable to oral carbidopa/levodopa, the dopamine agonist tavapadon, CVN424 as a novel therapy not targeting the dopamine pathway, and ongoing stem cell and gene therapy developments, with stem cells capable of creating dopamine-producing cells entering phase 3 studies.

Recent Medical Advancements: Opportunities and Considerations

An expert discusses the extended form of carbidopa/levodopa (Crexont) for managing OFF episodes, highlighting trial results that show decreased OFF time and increased ON time, as well as the use of subcutaneous loading of medications in Parkinson disease, which was well tolerated with skin issues as the main adverse effects and resulted in increased ON time without worsening dyskinesia.

Parkinson Disease: Prevalence and Impact of OFF Episodes and Dyskinesia

An expert discusses how providers can accurately track episodes of OFF and dyskinesia, highlighting their impact on patients physically, socially, and psychologically, including the challenges dyskinesia poses for sleep and fine motor tasks.

Parkinson Disease

Latest News